Interaction between allopurinol and pyrazinamide
Authors:
- C GuyonnaudCGC Guyonnaud
- M ChaouMCM Chaou
- H DuwoosHDH Duwoos
- O LafontOLO Lafont
- 1 October 1988
- journal article
- research article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 1 (9) , 807-811
Abstract
Pyrazinamide (PZA) is increasingly used with isoniazid and rifampicin, in short-course antituberculous chemotherapy in service programme conditions. Complicating arthralgias occur due to hyperuricaemia induced by the inhibition of renal tubular secretion of uric acid by pyrazinoic acid, the main PZA metabolite. Allopurinol (Al), a hypouricaemic agent, provides no substantial clinical improvement. Pharmacokinetics of PZA and its metabolites were studied in six healthy volunteers, in a cross-over design, after a single oral dose of PZA alone and, in a second trial, after the same dose together with Al. Plasma and urinary concentrations were measured by high pressure liquid chromatography with a column of cation exchange resin. Analysis of the pharmacokinetic parameters showed that Al induced marked changes in levels of PZA metabolites and accumulation of pyrazinoic acid. Despite decreasing uric acid synthesis, allopurinol increased plasma concentrations of pyrazinoic acid, which is directly responsible for the inhibition of renal urate secretion. Other drugs, which do not involve xanthine oxidase inhibition, should be used in the treatment of this side effect of chemotherapy.Keywords
This publication has 9 references indexed in Scilit:
- Microdétermination du pyrazinamide et de ses métabolites (acide pyrazinoïque, acide hydroxy-5-pyrazinoïque, hydroxy-5-pyrazinamide, acide pyrazinurique) plasmatiques et urinaires par chromatographie en phase liquideJournal of Chromatography B: Biomedical Sciences and Applications, 1987
- ROUTINE APPLICATION OF A 6-MONTH ANTITUBERCULOUS CHEMOTHERAPY TO 300 PATIENTS1986
- THE BIOAVAILABILITY OF ISONIAZID, RIFAMPIN, AND PYRAZINAMIDE IN 2 COMMERCIALLY AVAILABLE COMBINED FORMULATIONS DESIGNED FOR USE IN THE SHORT-COURSE TREATMENT OF TUBERCULOSIS1986
- PHARMACOKINETIC STUDIES ON ANTITUBERCULOSIS REGIMENS IN HUMANS .1. ABSORPTION AND METABOLISM OF THE COMPOUNDS USED IN THE INITIAL INTENSIVE PHASE OF THE SHORT-COURSE REGIMENS - SINGLE ADMINISTRATION STUDY1985
- SUPERVISED 6-MONTHS TREATMENT OF NEWLY DIAGNOSED PULMONARY TUBERCULOSIS USING ISONIAZID, RIFAMPIN, AND PYRAZINAMIDE WITH AND WITHOUT STREPTOMYCIN1984
- Role of rifampicin in arthralgia induced by pyrazinamideTubercle, 1983
- Double blind controlled comparison of aspirin, allopurinol and placebo in the management of arthralgia during pyrazinamide administrationTubercle, 1979
- Observations on the reduction of the renal elimination of orate in man caused by the administration of pyrazinamideTubercle, 1976
- Effect of Pyrazinamide and Pyrazinoic Acid on Urate Clearance and Other Discrete Renal Functions.Experimental Biology and Medicine, 1957